BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3（GPC3）

BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial

BioCity to Present Preliminary Phase I Results of BC3195 (CDH3 ADC) and Clinical Results from Two Trials of SC0245 (ATR Inhibitor) at 2024 ASCO Annual Meeting